InterMune Halts Phase III Actimmune Lung Disease Trial
Company will focus on pirfenidone for idiopathic pulmonary fibrosis after Actimmune failed to show a statistically significant treatment effect over placebo.
Company will focus on pirfenidone for idiopathic pulmonary fibrosis after Actimmune failed to show a statistically significant treatment effect over placebo.